Mydecine Innovations Group Inc. (C:MYCO*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Mar 27, 2024 05:00 pm ET
Mydecine Innovations Group Inc. Announces Closing of Share for Debt Settlement
VANCOUVER, BC – (TheNewswire / 27 March 2024) Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (FSE: 0NFA) (OTC: MYCOF) (the “Company” or “Mydecine”) announces that it has closed a debt settlement (the “Debt Settlement”) to partially settle outstanding debts owed to a creditor (the “Creditor”) for legal services rendered.
Mar 20, 2024 03:00 pm ET
Mydecine Innovations Group Inc. Announces Share for Debt Settlement
VANCOUVER, BC / TheNewswire / 20 March 2024 -- Mydecine Innovations Group Inc. (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “Company” or “Mydecine”) announced that it has entered into a debt settlement agreement (the “Settlement Agreement”) to partially settle outstanding debts owed to a creditor (the “Creditor”) for legal services rendered. Pursuant to the Settlement Agreement, the Company has agreed to issue an aggregate of 2,941,176 common shares (“Shares”) at a deemed price of $0.017 per Share, based on a 20-day VWAP (the “Share Settlement”). The Company anticipates closing the
Feb 07, 2024 05:01 pm ET
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two...
Feb 02, 2024 04:05 pm ET
Mydecine Innovations Group Announces Director Resignation
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore...
Dec 18, 2023 02:00 am ET
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has...
Nov 28, 2023 04:05 pm ET
Mydecine Announces Update Regarding the Special Access Program
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Nov 17, 2023 12:02 pm ET
Canadian Securities Exchange Reports October 2023 Performance Figures
Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2023.
Oct 31, 2023 02:00 am ET
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a...
Oct 26, 2023 02:00 am ET
Mydecine Provides Q4 2023 Business Update
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with...
Oct 18, 2023 04:15 am ET
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector.
Oct 10, 2023 02:00 am ET
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health...
Oct 05, 2023 05:01 pm ET
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Sep 27, 2023 05:18 pm ET
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Sep 20, 2023 12:12 pm ET
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Sep 19, 2023 04:01 pm ET
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Sep 15, 2023 05:30 pm ET
Mydecine Innovations Group Files Prospectus Supplement
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Aug 30, 2023 04:01 pm ET
Mydecine Announces Conditional Approval of CSE Listing
Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities...
Aug 14, 2023 08:32 pm ET
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on...
Jul 21, 2023 05:30 pm ET
Mydecine Innovations Group Provides Corporate Update
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Jul 05, 2023 04:01 pm ET
Mydecine Reports its Special Meeting Results
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
May 29, 2023 07:42 pm ET
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
May 16, 2023 04:01 pm ET
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
May 10, 2023 04:05 pm ET
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Apr 24, 2023 11:16 am ET
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Apr 19, 2023 05:04 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
VANCOUVER, BC, April 19, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated March 10, 2023 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement")
Apr 10, 2023 02:55 pm ET
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
VANCOUVER, BC, April 10, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated March 10, 2023, the Company has filed a shelf prospectus supplement (the "Prospectus S
Apr 03, 2023 06:00 am ET
Mydecine Innovations Group Provides Corporate Update
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Mar 31, 2023 08:21 pm ET
Mydecine Reports Financial Results for the Year Ended December 2022
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial...
Mar 15, 2023 10:25 am ET
MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT
DENVER, March 15, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, today announced that it has entered into a third Common Share Subscription Agreement, effective March 10th, 2023 (the "Subscription Agreement") with a third-party investor in the Company (the "Investor"). The Subscription Agreement allows the Company to issue and sell up to $10,000,
Mar 06, 2023 07:00 am ET
Mydecine Announces Debt Settlements
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Feb 23, 2023 02:58 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Feb. 23, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in con
Feb 22, 2023 07:57 am ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Feb. 22, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in connec
Feb 10, 2023 02:24 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Feb. 10, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in con
Jan 19, 2023 12:51 pm ET
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Jan. 19, 2023 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated August 26, 2022, the Company has filed a shelf prospectus supplement (the "Prospectus Suppleme
Dec 12, 2022 11:39 am ET
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is...
Dec 09, 2022 05:54 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Dec. 9, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in conn
Nov 28, 2022 07:38 pm ET
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Nov. 28, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated August 26, 2022, the Company has filed a shelf prospectus supplement (the "Prospectus Suppleme
Nov 21, 2022 12:01 pm ET
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Nov 14, 2022 05:44 pm ET
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial...
Sep 23, 2022 11:35 am ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO
DENVER, Sept. 23, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in co
Sep 14, 2022 07:35 pm ET
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, Sept. 14, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated August 26, 2022, the Company has filed a shelf prospectus supplement (the "Prospectus Supplem
Sep 01, 2022 10:33 am ET
IIROC Trade Resumption - MYCO
TORONTO, Sept. 1, 2022 /CNW/ - Trading resumes in:
Sep 01, 2022 10:00 am ET
Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Sep 01, 2022 08:32 am ET
IIROC Trading Halt - MYCO
TORONTO, Sept. 1, 2022 /CNW/ - The following issues have been halted by IIROC:
Aug 29, 2022 04:00 pm ET
Mydecine Innovations Group Announces Common Share Subscription Agreement
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Aug 19, 2022 12:09 pm ET
IIROC Trade Resumption - MYCO
TORONTO, Aug. 19, 2022 /CNW/ - Trading resumes in:
Aug 19, 2022 11:06 am ET
Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Aug 15, 2022 09:46 pm ET
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months...
Aug 12, 2022 02:05 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS
DENVER, Aug. 12, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have recently resigned as directors of the Company.
Aug 12, 2022 10:55 am ET
IIROC Trading Halt - MYCO
TORONTO, Aug. 12, 2022 /CNW/ - The following issues have been halted by IIROC:
Jul 19, 2022 07:00 am ET
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has successfully synthesized...
Jun 17, 2022 07:00 am ET
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration...
Jun 09, 2022 07:00 am ET
Mydecine Provides Company Update; Welcomes New Board Member
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today provided an update on clinical trial and...
May 27, 2022 09:22 am ET
Mydecine Announces Closing of Overnight Marketed Public Offering of Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
May 19, 2022 09:31 am ET
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
May 19, 2022 08:08 am ET
IIROC Trade Resumption - MYCO
TORONTO, May 19, 2022 /CNW/ - Trading resumes in:
May 18, 2022 03:37 pm ET
Mydecine Overnight Marketed Public Offering of Units
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
May 18, 2022 03:25 pm ET
IIROC Trading Halt - MYCO
TORONTO, May 18, 2022 /CNW/ - The following issues have been halted by IIROC:
May 16, 2022 09:28 pm ET
Mydecine Announces First Quarter 2022 Financial Results and Highlights
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a...
May 02, 2022 03:57 pm ET
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
DENVER, May 2, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated March 18, 2022 and the subsequent filing of a second shelf prospectus supplement (the "Prospectus Supplement") in connection therewith on April 27, 2022, the Company has closed the second issuance (the "Offering") under the Subscription Agreement.
Apr 27, 2022 09:31 pm ET
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT
DENVER, April 27, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is pleased to announce that in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor in the Company (the "Investor") dated March 18, 2022, the Company has filed a shelf prospectus supplement (the "Prospectus Supplement") to the Company's Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the pr
Apr 13, 2022 05:05 pm ET
Mydecine Announces Reverse Stock-Split
DENVER, April 13, 2022 /CNW/ - Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), today announces its Board of Directors has voted in favour of completing a reverse stock-split, thereby consolidating all of the Company's issued and outstanding common shares ("Common Shares") on the basis of one (1) post-consolidation Common Share for every fifty (50) pre-consolidation Common Shares (the "Consolidation").
Mar 31, 2022 10:03 pm ET
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a...
Mar 31, 2022 03:45 pm ET
Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement
DENVER, March 31, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") on March 18, 2022 and the subsequent filing of a shelf prospectus supplement (the "Prospectus Supplement") in connection therewith on March 21, 2022, the Company has closed the first tranche (the "Offering") under the Subscription Agreement of 3,527,337 common shares in the capital
Mar 24, 2022 07:30 am ET
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced it has received conditional...
Mar 03, 2022 07:30 am ET
Mydecine To Attend March Investor Conferences
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the company will be attending...
Mar 01, 2022 07:30 am ET
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and...
Feb 16, 2022 07:30 am ET
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the inclusion of a novel...
Feb 08, 2022 07:30 am ET
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that Health Canada has included...
Feb 03, 2022 07:30 am ET
Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale...
Feb 01, 2022 07:30 am ET
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced in preparation...
Jan 24, 2022 10:19 am ET
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership...
Jan 18, 2022 07:30 am ET
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada's Special Access Program
Under Mydecine's recently announced Special Access Support and Supply Program, the company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.
Jan 18, 2022 07:30 am ET
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has signed...
Jan 13, 2022 07:30 am ET
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they would be...
Jan 11, 2022 08:17 am ET
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Josh Bartch, CEO of Mydecine Innovations Group Inc.
via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part...
Jan 10, 2022 07:30 am ET
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they have...
Jan 07, 2022 04:30 pm ET
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the...
Jan 06, 2022 10:52 am ET
IBN (InvestorBrandNetwork) Announces Gamechangers LIVE Interview with Mydecine Innovations Group Inc. CEO Joshua Bartch
via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Joshua Bartch, Co-Founder, Chairman and CEO of Mydecine Innovations Group Inc. (NEO: MYCO)...
Dec 22, 2021 07:30 am ET
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the...
Dec 09, 2021 10:41 am ET
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered...
Dec 09, 2021 09:48 am ET
IIROC Trade Resumption - MYCO
TORONTO, Dec. 9, 2021 /CNW/ - Trading resumes in:
Dec 09, 2021 08:40 am ET
IIROC Trading Halt - MYCO
TORONTO, Dec. 9, 2021 /CNW/ - The following issues have been halted by IIROC:
Dec 06, 2021 07:30 am ET
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a...
Nov 16, 2021 07:30 am ET
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today reported its financial...
Nov 10, 2021 07:30 am ET
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that Dr....
Nov 04, 2021 08:30 am ET
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More.”...
Nov 03, 2021 07:30 am ET
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of...
Nov 02, 2021 08:30 am ET
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands in the InvestorBrandNetwork (“IBN”), a multifaceted...
Oct 29, 2021 07:30 am ET
Mydecine to Participate in Wonderland: Miami on November 8-9, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the treatment of mental health disorders and addiction, today announced that it will...
Oct 27, 2021 07:30 am ET
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that it has...
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
Oct 18, 2021 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Oct 11, 2021 09:25 am ET
KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 
Oct 06, 2021 07:30 am ET
Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
DENVER, Oct. 6, 2021 /PRNewswire/ -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
Oct 05, 2021 07:30 am ET
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug...
Oct 01, 2021 07:30 am ET
Mydecine Completes Spin-Out of U.S. Cannabis Assets
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has completed its previously announced...
Sep 24, 2021 04:40 pm ET
Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries
Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (“Mydecine” or the “Company”) is pleased to announce the previously announced spin-out transaction, to be implemented through a statutory plan of arrangement (the “Arrangement”) between Mydecine and ALT House Cannabis Inc. (“Spinco”) has received the requisite shareholder approval at Mydecine’s annual general and special meeting of shareholders held September 20, 2021 (the “Meeting”). Mydecine shareholders have voted 99.939% in favour of approving the Arrangement at the Meeting, and the Company rec
Sep 22, 2021 07:30 am ET
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has filed its final patent application with the...
Sep 07, 2021 07:30 am ET
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biopharmaceutical company focused on the treatment of mental health and addiction, announced it has partnered with Principal Investigator Dr. Matthew Johnson of Johns Hopkins...
Sep 02, 2021 07:30 am ET
Mydecine to Participate in Upcoming Conferences in September 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and addiction, today announced that Josh Bartch,...
Aug 24, 2021 03:30 pm ET
Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), is pleased to announce that it has filed and mailed its management information circular (the “Information Circular”) and related meeting and proxy materials for...
Aug 18, 2021 07:30 am ET
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, with research to be led by Professor of Psychiatry and Behavioral Sciences at Johns...
Aug 17, 2021 11:58 am ET
CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business News — BTV-Business Television explores the burgeoning sector that has captured the attention of investors - psychedelics.
Aug 17, 2021 06:00 am ET
BTV Examines the Rapidly Expanding Psychedelics Market
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business News — BTV-Business Television explores the burgeoning sector that has captured the attention of investors - psychedelics.
Aug 16, 2021 04:55 pm ET
Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jul 28, 2021 07:30 am ET
Mydecine to Participate in Upcoming Investor Events in August 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jul 21, 2021 07:30 am ET
Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jul 13, 2021 07:30 am ET
Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jun 24, 2021 07:30 am ET
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jun 23, 2021 07:30 am ET
Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jun 16, 2021 07:30 am ET
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jun 08, 2021 07:30 am ET
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jun 03, 2021 07:30 am ET
Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 25, 2021 07:30 am ET
Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 19, 2021 07:30 am ET
Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 18, 2021 07:30 am ET
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 10, 2021 07:30 am ET
Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 05, 2021 07:30 am ET
Mydecine Announces Partnership with LeadGen Labs
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
May 03, 2021 07:30 am ET
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Apr 26, 2021 07:30 am ET
Mydecine to Report Full Year 2020 Financial Results on May 3, 2021
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Apr 13, 2021 07:30 am ET
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Apr 07, 2021 07:30 am ET
Mydecine Announces API-naming structure of Four Lead Candidates and Prepares for Pre-IND
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Apr 07, 2021 07:30 am ET
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Mar 23, 2021 09:30 am ET
Mydecine Innovations Group Graduates Listing To NEO Exchange
NEO is excited to announce that Mydecine Innovations Group (“Mydecine” or the “Company”), a psychedel
Mar 23, 2021 07:30 am ET
Mydecine Innovations Group Announces Migration to NEO Exchange
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Mar 16, 2021 07:30 am ET
Mydecine Innovations Group Provides Update on European Operations
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine...
Mar 15, 2021 10:44 pm ET
Mydecine Announces Change of Auditor
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), announces that the board of directors of the Company has appointed MNP LLP, Chartered Professional Accountants as the Company’s new auditor, replacing SHIM & Associates LLP (“SHIM”), Chartered Professional Accountant.
Mar 10, 2021 07:30 am ET
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that it has entered into an arrangement agreement dated March 10, 2020 (the “Arrangement Agreement”) with a newly-incorporated...
Mar 01, 2021 07:30 am ET
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative...
Feb 24, 2021 07:00 am ET
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Feb 17, 2021 07:00 am ET
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology
Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world's-first telemedicine application...
Feb 12, 2021 09:08 am ET
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce the closing of its previously-announced bought-deal public offering led by Canaccord Genuity Corp. (“Canaccord” or the “Underwriter”) pursuant to which the Company issued 34,500,000 units of the Company (the “Units”) at a price of C$0.50 per Unit (the “Issue Price”) for aggregate gross proceeds to the Company of C$17,2
Feb 09, 2021 02:29 pm ET
Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed its final short form prospectus (the “Prospectus”) with the securities commissions or similar authorities in each province of Canada, other than Quebéc.
Feb 05, 2021 08:06 am ET
Mydecine Innovations Group Files Amended and Restated Financial Statements
Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) (FSE: 0NFA) announces it has filed amended and restated unaudited condensed interim consolidated financial statements for the nine-month period ended September 30, 2020 (the “Restated Statements”) and related amended and restated management discussion and analysis (“Restated MD&A” and together with the Restated Statements, the “Restated Documents”).
Feb 03, 2021 07:30 am ET
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Feb 01, 2021 07:30 am ET
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jan 28, 2021 07:30 am ET
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine...
Jan 27, 2021 07:30 am ET
Mydecine Innovations Group Files Application to list to the NASDAQ
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jan 22, 2021 07:30 am ET
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jan 21, 2021 04:20 pm ET
Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities commissions or similar authorities in each province of Canada, other than Quebéc, and entered into an underwrit
Jan 21, 2021 04:15 pm ET
Mydecine Announces Change of Auditor
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), announces that the board of directors of the Company has appointed SHIM & Associates LLP, Chartered Professional Accountants as the Company’s new auditor, replacing MNP LLP (“MNP”), Chartered Professional Accountant.
Jan 20, 2021 12:43 pm ET
KILL Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Miller Thomson LLP requests that their press release NewsItemId: 20210120005543 “Mydecine Innovations Group Upsizes Previously Announced Bought Deal” be killed.
Jan 20, 2021 12:42 pm ET
KILL Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Miller Thomson LLP requests that their press release NewsItemId: 20210120005542 “Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units” be killed.
Jan 20, 2021 11:00 am ET
Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp. (“Canaccord Genuity” or the “Underwriter”). Canaccord Genuity has agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 30,000,000 units of the
Jan 20, 2021 10:58 am ET
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity” or the “Underwriter”), pursuant to which Canaccord Genuity has agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 20,000,000 units of the Company (the “Units”) at a price of
Jan 14, 2021 10:53 am ET
IIROC Trade Resumption - MYCO
VANCOUVER, BC, Jan. 14, 2021 /CNW/ - Trading resumes in:
Jan 14, 2021 10:28 am ET
Mydecine Innovations Group Upsizes Previously Announced Bought Deal
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 14, 2021 08:43 am ET
IIROC Trading Halt - MYCO
VANCOUVER, BC, Jan. 14, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 14, 2021 06:10 am ET
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jan 11, 2021 12:36 pm ET
KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- KCSA Strategic Communications, an integrated strategic communications firm specializing in public relations, investor relations and social media, today announced that it will host its inaugural virtual Psychedelics Investor Conference on Tuesday, January 26, 2021 and Wednesday, January 27, 2021 from 9:00am – 12:30pm ET.
Jan 11, 2021 07:30 am ET
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jan 07, 2021 07:30 am ET
Mydecine Innovations Group Shares Intellectual Property Update
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for...
Jan 05, 2021 07:30 am ET
Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine...
Dec 21, 2020 07:30 am ET
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use,...
Dec 15, 2020 07:30 am ET
Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for...
Dec 10, 2020 07:30 am ET
Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for...
Dec 08, 2020 07:30 am ET
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for...
Nov 24, 2020 01:22 am ET
Mydecine Innovations Group to Restate Financial Statements
Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30,...
Nov 17, 2020 08:00 am ET
Mydecine Innovations Group Offers Management and Clinical Trials Update
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for...
Nov 06, 2020 07:30 am ET
Mydecine Innovations Group Retains KCSA Strategic Communications
NEW YORK, Nov. 6, 2020 /PRNewswire/ -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has retained KCSA Strategic Communications as its agency of record (AOR) to implement a comprehensive, strategic communications program targeted at educating the investment and biopharma communities on its work and mission to advance psychedelic and functional fungi medicine. 
Oct 19, 2020 07:30 am ET
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London...
Oct 16, 2020 04:01 pm ET
Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange
MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London...
Oct 14, 2020 07:30 am ET
Mydecine Innovations Group subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding...
Oct 07, 2020 07:30 am ET
Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States...
Sep 30, 2020 01:25 pm ET
Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today
Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing,...
Sep 24, 2020 07:30 am ET
Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration
Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine" or the "Company"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform will be officially available for download from the iOS and...
Sep 17, 2020 07:30 am ET
Mindleap Health Implements HIPAA Compliance Standards and Appoints Former Canadian Ministry of Health Telemedicine Expert as Head of Program Management
Mydecine Innovations Group, Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), is pleased to announce that its wholly-owned subsidiary, Mindleap Health (“Mindleap”), has implemented a comprehensive information security rollout...
Sep 15, 2020 07:00 am ET
Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value. Topics that the special...
Sep 03, 2020 03:17 pm ET
Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days
Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine", “MIG” or the "Company") is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that...
Aug 25, 2020 01:40 pm ET
Mydecine Innovations Group Announces Extended Lock-Up Arrangement
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), today announced that it has engaged with certain shareholders to enter into voluntary lock-up agreements (the “Lock-up Agreements”) applying resale...
Aug 18, 2020 07:30 am ET
Mydecine™ Launches World's First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise
Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine™" or the "Company") is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell,...
Aug 13, 2020 07:37 am ET
Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company"), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was...
Aug 12, 2020 07:30 am ET
Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector
Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" “MIG” or the "Company"), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position...
Aug 04, 2020 07:30 am ET
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic...
Jul 29, 2020 08:00 am ET
Ex-Canopy Growth Geneticist Turns His Focus to Psychedelics -- CFN Media
Whitefish, Montana--(Newsfile Corp. - July 29, 2020) -  CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing genetics research in the psychedelics space.
Jul 27, 2020 09:22 am ET
Mydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMO
DENVER, July 27, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company's new Chief Marketing Officer ("CMO"). 
Jul 24, 2020 05:17 pm ET
Mydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMO
DENVER, July 24, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company's new Chief Marketing Officer ("CMO"). 
Jul 21, 2020 01:57 am ET
Mindleap Health Signs Agreement with Brightmind to Launch Comprehensive Meditation Program
DENVER, July 21, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health Inc. ( "Mindleap" ) has signed an agreement dated July 21, 2020  with Brightmind ("Brightmind") to launch a comprehensive meditation program on Mindleap's advanced digital health platform. Under the terms of the agreement Brightmind will provide specialised meditation content to Mindleap and Mindleap will make that content available for purchase on the platform.
Jul 16, 2020 07:30 am ET
Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute
DENVER, July 16, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in veterans and frontline workers, has entered into a collaborative relationship with Leiden University Medical Center of The Netherlands ("LUMC") for the initiation of clinical trials. The project, "NeuroPharm Vete
Jul 16, 2020 12:30 am ET
Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute
DENVER, July 16, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in veterans and frontline workers, has entered into a collaborative relationship with Leiden University Medical Center of The Netherlands ("LUMC") for the initiation of clinical trials. The project, "NeuroPharm Vete
Jul 14, 2020 07:30 am ET
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc.
DENVER, July 14, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release on June 10, 2020, it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") for the acquisition (the " Acquisition ") of 100% of NeuroPharm Inc. ("NeuroPharm"), a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States veteran communities.
Jul 14, 2020 12:30 am ET
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans
DENVER, July 14, 2020 /CNW/ --  Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release on June 10, 2020, it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") for the acquisition (the " Acquisition ") of 100% of NeuroPharm Inc. ("NeuroPharm"), a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States veteran communities.
Jul 07, 2020 07:30 am ET
Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to Its Scientific Advisory Board
VANCOUVER, British Columbia, July 7, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.
Jul 07, 2020 12:30 am ET
Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board
VANCOUVER, British Columbia, July 7, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.
Jun 30, 2020 07:30 am ET
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
VANCOUVER, British Columbia, June 30, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.
Jun 24, 2020 08:00 am ET
What Is the Most Vital Part of an Effective Psychedelic Treatment?
Whitefish, Montana--(Newsfile Corp. - June 24, 2020) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing psychedelic treatment, aftercare, and Mindleap Health's innovative approach to the practice.
Jun 23, 2020 07:30 am ET
Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist
VANCOUVER, British Columbia, June 23, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.
Jun 23, 2020 12:40 am ET
Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist
VANCOUVER, British Columbia, June 23, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company") is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.
Jun 17, 2020 08:26 am ET
Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
VANCOUVER, British Columbia, June 17, 2020 /CNW/ -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry.
Jun 17, 2020 08:26 am ET
Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
VANCOUVER, British Columbia, June 17, 2020 /PRNewswire/ -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry.
Jun 17, 2020 12:30 am ET
Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
VANCOUVER, British Columbia, June 17, 2020 /CNW/ -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry.
Jun 17, 2020 12:30 am ET
Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
VANCOUVER, British Columbia, June 17, 2020 /PRNewswire/ -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry.
Jun 15, 2020 07:30 am ET
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
VANCOUVER, British Columbia, June 15, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce  the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API"), a translational commercial drug development institute hosted in the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
Jun 12, 2020 02:39 pm ET
IIROC Trade Resumption - MYCO
VANCOUVER, BC, June 12, 2020 /CNW/ - Trading resumes in:
Jun 12, 2020 02:30 pm ET
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
VANCOUVER, British Columbia, June 12, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API"), a translational commercial drug development institute hosted in the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
Jun 11, 2020 10:49 am ET
IIROC Trading Halt - MYCO
VANCOUVER, BC, June 11, 2020 /CNW/ - The following issues have been halted by IIROC:
Jun 10, 2020 09:28 am ET
IIROC Trade Resumption - MYCO
VANCOUVER, BC, June 10, 2020 /CNW/ - Trading resumes in:
Jun 10, 2020 12:30 am ET
Mydecine Innovations Group to Acquire NeuroPharm Inc.
VANCOUVER, British Columbia., June 10, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce it has signed a non-binding Letter of Intent ("LOI") dated June 9, 2020 to acquire NeuroPharm Inc., ("NeuroPharm") a Canadian-based healthcare company working to deploy the power of nature's medicine for the wellness of veterans, EMS and front line personnel in  North America and globally (the "Acquisition").
Jun 10, 2020 12:30 am ET
Mydecine Innovations Group to Acquire NeuroPharm Inc.
VANCOUVER, British Columbia., June 10, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce it has signed a non-binding Letter of Intent ("LOI") dated June 9, 2020 to acquire NeuroPharm Inc., ("NeuroPharm") a Canadian-based healthcare company working to deploy the power of nature's medicine for the wellness of veterans, EMS and front line personnel in  North America and globally (the "Acquisition").

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.